New mRNA vaccine targets RSV in early human trial
NCT ID NCT07289503
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new mRNA vaccine called ABO1105 against respiratory syncytial virus (RSV). Around 96 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABO1105 (mRNA vaccine)
- What this could lead to
- If successful, this could lead to a safe and effective vaccine against RSV, a common respiratory virus.
- What could go wrong
- This is an early Phase 1 trial with only 96 participants, so safety and immune response are still unproven. The vaccine may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baise Center For Disease Control & Prevention
Baise City, Baise, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a vaccine given during pregnancy shield infants from a deadly virus?
- Moderna's mRNA vaccine cocktail passes early safety check
- New RSV vaccine shows promise for seniors in korea
- Could a shot during pregnancy shield babies from RSV?
- RSV booster shot shows promise for seniors
- New mRNA RSV vaccine shows promise for older adults in phase 3 trial